Figure 4.

Nuclear localization of NLRP3 positively regulates IL-4 in malignant CD4⁺ T cells from CTCL patients. (A) HTB-176 cells were stimulated with PMA/ionomycin with or without an NLRP3 assembly inhibitor (MCC950). Representative immunofluorescence (IF) for NLRP3 (AF-488) and IL-4 (AF-594) expression. Quantification of (B) NLRP3 nuclear expression and (C) total expression of IL-4 in the microphotographs of the different treatments (n = 4). (D) Flow cytometric analysis of cells treated as in (A), representative histogram and MFI plot of IL-4 expression (n = 3). (E) Z-stack imaging and reconstruction depicting NLRP3 expression in HTB-176 cells not stimulated or after treatment with PMA plus the NLRP3 assembly inhibitor ( Supplementary Videos 3 and 4 , respectively). Error bars = SEM; **P < 0.01; ***P < 0.001. Scale bars= 20 nm.